TITLE

Novartis' Zelmac work lands at Viagra agency

AUTHOR(S)
Goetzl, David
PUB. DATE
April 2000
SOURCE
Advertising Age;4/24/2000, Vol. 71 Issue 18, p98
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Novartis Pharmaceuticals Corp. will market a product for irritable bowel syndrome, Zelmac. Zelmac has received priority review status from the United States Food and Drug Administration. Cline, Davis & Mann agency will handle the Zelmac drug advertising account.
ACCESSION #
3023885

 

Related Articles

  • Novartis' Zelmac work lands at Viagra agency. Goetzl, David // Advertising Age;4/24/2000, Vol. 71 Issue 18, p98 

    The article reports that Novartis Pharmaceuticals Corp. will market a product for irritable bowel syndrome, Zelmac. Zelmac has received priority review status from the United States Food and Drug Administration. Cline, Davis & Mann agency will handle the Zelmac drug advertising account.

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Clinical Oncology Alert;May2007 Pharmacology Watch, p1 

    The article reports on the decision by the U.S. Food & Drug Administration (FDA) to remove tegaserod, a drug from Novartis Pharmaceutical for irritable bowel syndrome, from the market due to findings of increased risk of serious cardiovascular events associated with use of the drug. The decision...

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Clinical Cardiology Alert;May2007 Pharmacology Watch, p1 

    The article announces the decision of the U.S. Food and Drug Administration (FDA) to remove Novartis Pharmaceutical's Tegaserod drug for irritable bowel syndrome (IBS) from the market due to increased risk of serious cardiovascular events. The drug was approved in 2002 for women with IBS whose...

  • IBS-Drug Treatment Pulled, CV Side Effects.  // Primary Care Reports;May2007, Vol. 13 Issue 5, p1 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to remove from the market Novartis Pharmaceutical's Tegaserod for irritable bowel syndrome due to findings of increased risk of serious cardiovascular events associated with use of the drug. Report says that the...

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Neurology Alert;May2007, Vol. 25 Issue 9, p1 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to remove the tegaserod drug for irritable bowel syndrome manufactured by Novartis Pharmaceutical from the market. A study found that the drug was associated with increased risk of cardiovascular events. The drug...

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Infectious Disease Alert;May2007, Vol. 26 Issue 8, p1 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to prohibit the sale of Tegaserod (Zelnorm), a drug for irritable bowel syndrome from Novartis Pharmaceuticals, based on findings of increased risk of serious cardiovascular events associated with the use of the...

  • Antidote. Siegel, Marc // Medical Marketing & Media;May2007, Vol. 42 Issue 5, p12 

    The author reflects on the drug Zelnorm, a treatment for irritable bowel Syndrome manufactured by Novartis Pharmaceuticals Corp., which was recently recalled from the U.S. drug market due to its side effects. According to the author, people currently live in an unhealthy climate of drug company...

  • Novartis begins streamlining its roster. Arnold, Matthew // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p11 

    This article reports that Novartis Pharmaceuticals Corp. heard pitches from advertising agencies last month as it seeks lo consolidate global consumer and professional advertising business into three or four integrated shops. The company has implemented a more "consumer-centric" marketing model...

  • Converging Models. Hogan, Cynthia // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p90 

    Takes a look at the marketing efforts of Novartis for Visudyne (verteporfin), a therapy that helps preserve vision in patients suffering from the wet form of age-related macular degeneration (AMD), and to reposition Lamisil, a treatment for onychomychosis or nail fungal infections. Problems met...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics